RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

JOURNAL ARTICLE published 1 April 2011 in Journal of Clinical Oncology

Authors: Nicholas J. Robert | Véronique Diéras | John Glaspy | Adam M. Brufsky | Igor Bondarenko | Oleg N. Lipatov | Edith A. Perez | Denise A. Yardley | Stephen Y.T. Chan | Xian Zhou | See-Chun Phan | Joyce O'Shaughnessy